In human ovarian cancer, IL-22-producing ILC3s prevent tumor-infiltrating lymphocyte activation and proliferation (27), whereas the release of IL-22 and IL-17 by ILC3s modulates intestinal immune pathology (77). Here, IL17A is linked to neoplasm.